TCWA
EGRX

Ten Capital Wealth Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Ten Capital Wealth Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-87
Closed -$2.47K – 568
2023
Q1 		$2.47K Sell
87
-49
-36% -$1.46K ﹤0.01% 455
2022
Q4 		$3.98K Hold
136
– – ﹤0.01% 404
2022
Q3 		$4K Buy
+136
New +$4.99K ﹤0.01% 443

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ten Capital Wealth Advisors's EGRX Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 87 shares — an estimated $2.47K sold.

Ten Capital Wealth Advisors first reported a position in EGRX in Q3 2022 and held it in 3 quarters. The position peaked at $4K in Q3 2022. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Ten Capital Wealth Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Ten Capital Wealth Advisors sold 87 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $2.47K.
  • Ten Capital Wealth Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2022 and held it in 3 quarters.
  • Ten Capital Wealth Advisors's Eagle Pharmaceuticals, Inc. position peaked at $4K in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.